Industry News

Boston Herald The Ticker column [Boston Herald]
OPKO Health, Inc., announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc., by way of a plan of arrangement which was approved by Transition Therapeutics’ shareholders at their meeting held on August 25, 2016. Pursuant to the Arrangement, shareholders of Transition Therapeutics will receive an aggregate of approximately 6.4 million shares of OPKO common stock, or 0.1657 shares of OPKO common stock for each common share of..."/>
OPKO Health Completes Acquisition of Transition Therapeutics
IndAS and why the numbers don't add up [Mint, New Delhi]
Kamada Ltd. announced today that it had attained positive results, meeting the primary endpoint, in a phase 2 trial of its Alpha-1 Antitrypsin Deficiency treatment. Following this announcement, Kamada's stock jumped 13%, and the company is traded at a market cap of NIS 680 million. The trial was carried out in the US, and is aimed at future registration of the product there."/>
Kamada succeeds in phase 2 inhaled drug trial [Globes, Tel Aviv, Israel]
IndAS and why the numbers don't add up [Mint, New Delhi]
Gilead Sciences has infringed, and continues to infringe, on the university's intellectual property rights by selling three medicines that contain the drug sofosbuvir. The drug is included in the brand-name medications..."/>
University of Minnesota sues Gilead Sciences over patents for hepatitis drugs [Star Tribune (Minneapolis)]
St. Jude Medical don't appear supported by evidence offered so far, an independent analysis has found. The analysis by researchers at the University of Michigan on Tuesday came as St."/>
Outside research team questions St. Jude hacking claims [Star Tribune (Minneapolis)]
Rock Creek Pharmaceuticals Inc. has told the U.S. Securities and Exchange Commission that it has received an "event default redemption notice" from Hudson Bay Master Fund Ltd., a noteholder in the company's October 2015 private placement of $20 million. The Manatee-based clinical-stage drug-development company also says it has received a similar notice from Tenor Capital Management, on behalf of Alto Opportunity Master Fund SPC, another noteholder."/>
Rock Creek receives default notices from two noteholders [Sarasota Herald-Tribune, Fla.]
Centene Corp; and UPMC for You, which is owned by the University of Pittsburgh..."/>
Pa. picks three firms to manage Medicaid benefits for elderly and disabled [Philly.com]
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided an update today on the status of key clinical trials. Plantar Fasciitis Investigational New Drug Study Receives FDA Approval for Protocol..."/>
MiMedx Provides Update On Key Clinical Trials
Kewaunee Scientific Corporation today reported results for its first quarter ended July 31, 2016.. Sales for the quarter were $37,279,000, a 20% increase from sales of $31,089,000 in the prior year first quarter. Domestic sales for the quarter were $29,637,000, up 22% from sales of $24,315,000 in the first quarter of last year."/>
Kewaunee Scientific Reports Results for First Quarter
National Research Corporation today announced that its Board of Directors has declared a quarterly cash dividend of $0.08 per Class A share and$. 48 per Class B share payable Friday, October 14, 2016, to shareholders of record as of the close of business on Friday, September 30, 2016.. For more than 35 years, National Research Corporation has been at the forefront of patient-centered care, helping healthcare providers measure and improve quality and services..."/>
National Research Corporation Declares Quarterly Dividend
Valeant Pharmaceuticals International, Inc. today announced that Joseph C. Papa, Chairman and CEO, will participate in the following healthcare conferences in September:. Wells Fargo Healthcare Conference on Wednesday, September 7, at 3:30 p.m. ET at the Westin Waterfront Hotel in Boston; and, Morgan Stanley Global Healthcare Conference on Tuesday, September 13, at 9:10 a.m. ET at the Grand Hyatt Hotel in New York City.. A live webcast and audio..."/>
Valeant Pharmaceuticals To Participate In September Healthcare Conferences
Valeant Pharmaceuticals International, Inc. today announced that Joseph C. Papa, Chairman and CEO, will participate in the following healthcare conferences in September:. Wells Fargo Healthcare Conference on Wednesday, September 7, at 3:30 p.m. ET at the Westin Waterfront Hotel in Boston; and, Morgan Stanley Global Healthcare Conference on Tuesday, September 13, at 9:10 a.m. ET at the Grand Hyatt Hotel in New York City.."/>
Valeant Pharmaceuticals To Participate In September Healthcare Conferences
Thermo Fisher Scientific Inc.. The transaction is expected to be completed by the end of 2016, subject to the satisfaction of customary closing conditions, including applicable regulatory approvals.. FEI Company designs, manufactures and supports a broad..."/>
FEI Shareholders Approve Acquisition by Thermo Fisher Scientific
Castlight Health, Inc., a leading health benefits platform provider, today announced that President and Chief Operating Officer John Doyle will present at the Morgan Stanley Global Healthcare Conference 2016 in New York, NY. Castlight Health's presentation is scheduled for Monday, September 12, 2016 at 12:30 p.m. Eastern Time and will be webcast live. An archive of the presentation will be available for a limited time and will be accessible at www.castlighthealth.com in the..."/>
Castlight Health to Present at the Morgan Stanley Global Healthcare Conference 2016
Centene Corporation announced today that its Pennsylvania subsidiary, Pennsylvania Health& Wellness, has been selected by the departments of Human Services and Aging to serve enrollees in the Community HealthChoices program statewide, pending regulatory approval and successful completion of readiness review. The five-year agreement, with an option to renew for two additional years, is expected to commence July 1, 2017, in the Southwest zone."/>
Centene's Pennsylvania Subsidiary Awarded Statewide Community HealthChoices Managed Care Agreement
Revance Therapeutics, Inc., a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2016 Wells Fargo Securities Healthcare Conference in Boston, MA. Revance management is scheduled to present on Wednesday, September 7 at 9:55am ET. Interested parties can access the live audio webcast for both of these conferences from the Investor Relations..."/>
Revance to Participate in the 2016 Wells Fargo Securities Healthcare Conference

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary515 Articles
Information Technology470 Articles
Financials380 Articles
Industrials301 Articles
Health Care260 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.